4 Health Care Stocks With Whale Alerts In Today’s Session

Arrowhead Pharmaceuticals To Present Data On Plozasiran In Patients With Severe Hypertriglyceridemia At European Society Of Cardiology Congress

Arrowhead Pharma’s REDEMPLO Authorized In EU; Now Prescribable And Reimbursable In Germany For Familial Chylomicronaemia Syndrome

REDEMPLO® (plozasiran) is listed in the Lauer-Taxe® database as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronaemia syndrome (FCS), diagnosed either based on clinical

HC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $120

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and raises the price target from $115 to $120.

Arrowhead Pharma Q3 EPS $(1.36) Misses $(1.32) Estimate, Sales $75.253M Beat $54.294M Estimate

Arrowhead Pharma (NASDAQ:ARWR) reported quarterly losses of $(1.36) per share which missed the analyst consensus estimate of $(1.32) by 3.03 percent. This is a 7.94 percent decrease over losses of $(1.26) per share from

Gilead’s Trodelvy-Keytruda Combo Gets EU Approval for Metastatic Breast Cancer

Invesco Nasdaq Biotech vs. Invesco Pharma: How Do These ETFs Stack Up?

The Invesco Pharmaceuticals ETF (PJP) offers concentrated exposure to 29 pharma giants with better historical returns and lower volatility, while the Invesco Nasdaq Biotechnology ETF (IBBQ) provides broader diversification across 251 holdings at a lower expense ratio of 0.19% versus 0.57%. Despite IBBQ's cost advantage, PJP is recommended as the better buy due to its significantly larger asset base ($512.6M vs $81M), which addresses liquidity concerns.